{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:55:55Z","timestamp":1789433755740,"version":"build-2803163510"},"reference-count":37,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To describe and analyze the pharmacodynamic and pharmacokinetic properties and clinical evidence supporting the efficacy and use of cefepime-enmetazobactam (FEP-EMT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>A literature search was conducted using MEDLINE and EMBASE databases (January 2015 to May 2024). Search terms included: \u201ccefepime-enmetazobactam\u201d or \u201ccefepime\u201d or \u201cenmetazobactam\u201d or \u201ccefepime\u201d or \u201cnovel beta-lactamase inhibitor\u201d and \u201ccomplicated urinary tract infection\u201d or \u201ccUTI.\u201d Conference abstracts, bibliographies, clinical trials, and drug monographs were included for review.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction:<\/jats:title>\n                    <jats:p>Relevant studies in English and clinical trials conducted in humans were reviewed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>In February 2024, the Food and Drug Administration (FDA) approved the combination beta-lactam\/beta-lactamase inhibitor (BL\/BLI) FEP-EMT for the treatment of complicated urinary tract infections (cUTIs) and acute pyelonephritis following the completion of the Phase III ALLIUM trial comparing it to piperacillin-tazobactam (TZP). The trial resulted in 79.1% of the FEP-EMT group versus 58.9% of the TZP group meeting the primary outcome of clinical cure and microbiological eradication (95% CI 21.2 [14.3 to 27.9]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to Patient Care and Clinical Practice in Comparison to Existing Agents:<\/jats:title>\n                    <jats:p>This review describes the use of FEP-EMT for the treatment of cUTI and compares its use to other novel BL\/BLI combinations including utility in drug-resistant infections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>FEP-EMT provides an antimicrobial option to reduce overuse of carbapenems for extended spectrum beta-lactamase (ESBL) producing Enterobacteriaceae. However, unlike other novel BL\/BLI combinations, its limited spectrum of antibacterial effect for more difficult-to-treat pathogens and cost may also impact its overall utilization.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280241279904","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T06:23:27Z","timestamp":1727418207000},"page":"570-576","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":9,"title":["Cefepime-Enmetazobactam: A Drug Review of a Novel Beta-Lactam\/Beta-Lactamase Inhibitor"],"prefix":"10.1177","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-8098-0240","authenticated-orcid":false,"given":"Cameron","family":"Lanier","sequence":"first","affiliation":[{"name":"Johnson City Medical Center, Ballad Health, Johnson City, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Melton","sequence":"additional","affiliation":[{"name":"College of Pharmacy, The University of Tennessee Health Science Center, Knoxville, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Covert","sequence":"additional","affiliation":[{"name":"Bill Gatton College of Pharmacy, East Tennessee State University, Johnson City, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,9,27]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1086\/524891"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1186\/cc13948"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j4339"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.15620\/cdc:82532"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab560"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad428"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2017.06.010"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4666"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.2010.515588"},{"key":"e_1_3_2_11_2","unstructured":"Drug trials snapshots: EXBLIFEP. U.S. Food & Drug Administration. Published 2024. Accessed June 1 2024. https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/drug-trials-snapshots-exblifep"},{"key":"e_1_3_2_12_2","volume-title":"Exblifep (Cefepime-Enmetazobactam) [Package Insert]","author":"Allecra Therapeutics","year":"2024","unstructured":"Allecra Therapeutics. Exblifep (Cefepime-Enmetazobactam) [Package Insert]. Allecra Therapeutics; 2024."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00926-21"},{"key":"e_1_3_2_14_2","unstructured":"Cefepime and enmetazobactam. Pharmacology and pharmacokinetics. Lexicomp. Published 2024. Accessed July 22 2024. https:\/\/online.lexi.com\/lco\/action\/home"},{"key":"e_1_3_2_15_2","volume-title":"Maxipime (Cefepime) [Package Insert]","author":"Hospira","year":"2012","unstructured":"Hospira. Maxipime (Cefepime) [Package Insert]. Hospira; 2012."},{"key":"e_1_3_2_16_2","unstructured":"Cefepime. Administration and storage issues. Lexicomp. Published 2024. Accessed July 22 2024. https:\/\/online.lexi.com\/lco\/action\/home"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-022-01137-y"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkae058"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa511"},{"key":"e_1_3_2_20_2","unstructured":"National Center for Biotechnology Information. PubChem compound summary for CID 139593497 enmetazobactam hydriodide. Accessed July 22 2024. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Enmetazobactam-hydriodide"},{"key":"e_1_3_2_21_2","unstructured":"National Center for Biotechnology Information. PubChem compound summary for CID 123630 tazobactam. Accessed July 22 2024. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Tazobactam"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00105-19"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00078-20"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105925"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00514-19"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens4030620"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00033-15"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00180-20"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01468-20"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.17034"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz360.1341"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.12163"},{"key":"e_1_3_2_33_2","unstructured":"Tamma P Heil E Justo J et al Infectious Diseases Society of America antimicrobial-resistant treatment guidance: gram-negative bacterial infections. Infectious Diseases Society of America 2024. Version 4.0. https:\/\/www.idsociety.org\/globalassets\/idsa\/practice-guidelines\/amr-guidance\/4.0\/amr-guidance-4.02.pdf#page=1"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab045"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01676-21"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2024.107150"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00339-23"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304748"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280241279904","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280241279904","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280241279904","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:13:51Z","timestamp":1777374831000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280241279904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,27]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1177\/10600280241279904"],"URL":"https:\/\/doi.org\/10.1177\/10600280241279904","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,27]]}}}